Pharmaceuticals

[admin]

New version of Adis R&D Insight global pipeline database launched

24. September 2009 05:02

Wolters Kluwer Pharma Solutions, Inc., a leading provider of market data and competitive intelligence to the pharmaceutical and biotech industries, today introduced a powerful, new version of its popular Adis R&D Insight global pipeline database. Available immediately, the enhanced product quantifies probability of approval and revenue potential for thousands of drugs in development. The new Adis R&D Insight is the first research tool to become available that combines quantitative forecasting capabilities with a comprehensive collection of research on pipeline drugs.

"Many companies have been talking about the need for better products to aid the process of forecasting pipeline drugs," said Jeff Southwood, Senior Product Manager, Business Intelligence, Wolters Kluwer Pharma Solutions. "Today, we've delivered and made available one that sets a new standard by integrating forecasting with deep science."

Adis R&D Insight utilizes the intelligent forecasting of inThought, the company's pharmaceutical research service, to assign approvability ratings and generate revenue forecasts. Every active-development drug in the database is assigned an inThought Approvability Index (IAI), which assesses the progress of a drug candidate through clinical development. An evidence-based score is assigned for specific line items relating to safety, efficacy, trial design, and other factors in each phase of clinical development. InThought analysts continually update these scores based on clinical trial announcements, results, regulatory activity and other factors.

Complementing the IAI are detailed revenue models, addressing the market potential of approved drugs as well as developmental agents. Employing a proprietary model, inThought applies a consistent set of criteria across each assessment. Revenue models forecast seven years into the future and provide three years of historical data, and are developed separately for the U.S., Europe and Japan.

The new forecasting capabilities supplement a dedicated team of indication-area experts who track hundreds of developmental drugs on a daily basis by scouring published articles, conference abstracts, clinical trial registries, company websites, press releases and SEC findings, and compile findings into the database with links to key items.

A New Level of Transparency

Wolters Kluwer Pharma Solutions developed the product to provide unfettered access to the rationale behind its analysis. The current solution offers a level of transparency that is unavailable in any other pipeline product. A customer can drill-down into the source data to reveal events in the marketplace that influenced the analysis. For example, when an IAI is upgraded, a customer can link to abstracts associated with the event that led to the change.

"With this level of transparency, our clients understand how to assign value to these ratings," said Southwood.

Each IAI score also is given a second level of scrutiny in the form of a letter grade (A-F) to help verify how it compares to other drugs in the same class at a similar stage of development. This makes it easy to see the relative strength or weakness of a particular drug compared to others in its peer group.

The new forecasting features are fully integrated into the design of the product. "This approach provides greater versatility and depth of searching allowing access to every field within the database without limitation," added Southwood.

Adis R&D Insight is intended for pharma teams responsible for competitive intelligence, business development, and partnership and licensing research -- all of whom are tasked with developing their own revenue projections, market forecasts, and competitive intelligence research. Now these groups have an alternative resource to which they can compare their analysis.

Containing profiles for more than 25,000 drugs in development, Adis R&D Insight tracks and evaluates drugs worldwide through the entire development process, from discovery, through pre-clinical and clinical studies, to launch. Users can gather comprehensive drug information using customizable search criteria searchable by company, drug, indication and phase of development. Available now by subscription, learn more about the enhanced product at Wolters Kluwer Pharma Solutions.

Source: Wolters Kluwer :: Home

[admin3]

By Beverley Head
Tuesday, 06 April 2010 14:41

Business IT - Technology

Teradata’s push into the smaller end of the data warehousing market, and its more aggressive pricing policy, has effectively sliced $400,000 from Australian Pharmaceutical Industries’ IT budget over the next three years.

Brett Hart, manager of finance and business reporting for the pharmacy division which has pioneered the use of data warehousing and business intelligence for API, said that when the company first began its adventures in data warehousing two years ago it realised it would eventually have to upgrade its data warehouse facility and had budgeted accordingly.

He explained though that in the intervening two years Teradata – once a supplier focused on the big end of town - had pushed into the lower end of the data warehousing market and become much more aggressive on pricing. This he believed would save API $400,000 over the next three years compared to its initial data warehouse budget forecast.

API currently runs a 1 terabyte data warehouse, which following the upgrade has the capacity to grow to 6.7 terabytes.

The pharmacy division, which supplies products to more than 4,000 pharmacies nationwide, has been the first API cab off the rank to use the data warehouse. Late last year the organisation won an international award for its “integrated view of the business” which has been underpinned by the Teradata warehouse, analytical software from Informatica, and business intelligence software supplied by MicroStrategy.

Until the data warehouse based system was installed API relied on an ERP with some analytics overlaid for its information insights. This approach meant it would sometimes be 3 in the afternoon before management reports were available.

In addition the organisation had to cope with information being stored all over the enterprise. “Every nook and cranny had Excel spreadsheets to make sense of it,” Hart has acknowledged.

Now pharmacy data is combined into one data warehouse and management reports are available at the start of the business day.

Business users are also being encouraged to conduct their own ad hoc queries of the data warehouse, a trend Hart believes will continue. Acknowledging that to be successful; “We’ve got to convince the business that this is the way to go,” Hart said it would be important for managers to “accept responsibility” for their role in accessing the information that would help them run their operations, rather than waiting for IT to send them reports that IT thought might be useful.

Hart said that the appointment in December of Peter Hourihan as chief information officer at API, replacing Michael Vodicka, had prompted a planned extension of API’s data warehousing initiative.

Hourihan who also heads up the organisation’s group supply chain, has according to Hart, charged him with now exploring how business intelligence and data warehousing can be applied both to the retail arm of the business (the PriceLine stores) and its group supply operations.

The platform for this expanded application of the technology will be the new Teradata data warehouse appliance.

In a release issued today by Teradata, Hart claimed that the system upgrade: “Has increased our ability to make better, timelier decisions while also providing us the opportunity to integrate other business units’ data into the enterprise warehouse to accommodate future information requirements.”

API’s previous 550P data warehouse appliance has now been redeployed as a test and development platform.